Leisha A. Emens
Advanced in Inflammatory Breast Cancer

Dr. Leisha A. Emens

Oncology
600 N Wolfe St, Suite 4628, 
Baltimore, MD 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Inflammatory Breast Cancer
600 N Wolfe St, Suite 4628, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leisha Emens is an Oncologist in Baltimore, Maryland. Dr. Emens is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, and Ovarian Cancer.

Her clinical research consists of co-authoring 123 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Inflammatory Breast Cancer.

Specialties
Oncology
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

600 N Wolfe St, Suite 4628, Baltimore, MD 21287

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Converting HR+ Breast Cancer Into an Individualized Vaccine
Converting HR+ Breast Cancer Into an Individualized Vaccine
Enrollment Status: Recruiting
Publish Date: February 19, 2025
Intervention Type: Biological, Radiation, Drug
Study Drugs: Pembrolizumab, CDX-301
Study Phase: Phase 2
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
Enrollment Status: Recruiting
Publish Date: January 27, 2025
Intervention Type: Drug, Radiation
Study Drugs: Letrozole, Palbociclib
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab
Study Phase: Phase 2
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drug: NC762
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: April 10, 2023
Intervention Type: Drug
Study Drug: Bintrafusp alfa
Study Phase: Phase 2
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 31, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 1
Cytokine Expression During Radiation for Breast Cancer
Cytokine Expression During Radiation for Breast Cancer
Enrollment Status: Completed
Publish Date: October 08, 2020
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
View 11 Less Clinical Trials

123 Total Publications

SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development.
SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development.
Journal: Journal for immunotherapy of cancer
Published: May 26, 2025
Similar Doctors
Distinguished in Inflammatory Breast Cancer
Dr. David A. Riseberg
Oncology | Hematology
Distinguished in Inflammatory Breast Cancer
Dr. David A. Riseberg
Oncology | Hematology

St Paul Place Specialists Inc

301 Saint Paul St, 
Baltimore, MD 
 (1.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Riseberg is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Riseberg is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer. Dr. Riseberg is currently accepting new patients.

Antonio C. Wolff
Distinguished in Inflammatory Breast Cancer
Dr. Antonio C. Wolff
Oncology
Distinguished in Inflammatory Breast Cancer
Dr. Antonio C. Wolff
Oncology

Johns Hopkins University

600 N Wolfe St, Blalock 266, 
Baltimore, MD 
 (0.1 miles away)
410-502-4340
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Antonio Wolff is an Oncologist in Baltimore, Maryland. Dr. Wolff is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer. Dr. Wolff is currently accepting new patients.

Distinguished in Inflammatory Breast Cancer
Dr. Katherine H. Tkaczuk
Oncology
Distinguished in Inflammatory Breast Cancer
Dr. Katherine H. Tkaczuk
Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (1.9 miles away)
410-328-1230
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Katherine Tkaczuk is an Oncologist in Baltimore, Maryland. Dr. Tkaczuk is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. Dr. Tkaczuk is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Emens's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile